Werewolf Therapeutics Q2 net loss narrows to $5.1M; cash runway through Q4 2024; WTX-124 data expected 4Q23

Werewolf Therapeutics, Inc.

2023-Q2 EPS reported -$0.49

Net loss $5.1M ($0.16/diluted share) vs $14.6M ($0.83) in Q2 2022; collaboration revenue $8.1M (up from $4.1M).
Cash and equivalents $137.5M at June 30, 2023; restricted cash $21.2M; runway through at least Q4 2024.
R&D expenses fell to $9.6M from $13.9M YoY on lower manufacturing costs and purchase-order closeouts.
WTX-124 Phase 1/1b enrollment ongoing; initial monotherapy safety, PK, and biomarker data anticipated in 4Q 2023.
Jazz Pharmaceuticals' JZP898 (formerly WTX-613) IND cleared July 2023 under the Werewolf collaboration.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Werewolf Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: revenue $8.1 million, net income $5.1 million.

Period: the second quarter ended June 30, 2023
Revenue: $8.1 million
Net income: $5.1 million
Result: reported results

Exact text from the filing

Collaboration revenue was $8.1 million for the second quarter of 2023, compared to $4.1 million for the same period in 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Werewolf Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001785530-23-000027

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.